Involvement of endogenous gabaergic system in the modulation of gonadotropin secretion in normal cycling women

Gian Benedetto Melis, V. Mais, A. M. Paoletti, F. Beneventi, F. D. Petacchi, P. Fioretti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To investigate whether endogenous GABA participates in the control of gonadotropin secretion during the menstrual cycle, placebo or sodium valproate (DPA), an anticonvulsant drug which enhances endogenous GABA content by blocking GABA degradation, were administered to regularly cycling women both during early follicular and midluteal phase. In a first set of experiments, the effect of DPA administration (400 mg, orally) on basal gonadotropin secretion was evaluated in 13 subjects. During early follicular phase (n = 6), no significant changes In plasma gonadotropin levels were observed after DPA or placebo administration. Conversely, during midluteal phase (n = 7), DPA administration resulted in a significant fall (p <0.01) in plasma LH concentrations, with a maximal percent decrease of 41.8 ± 6.7% after 120 min. No changes in plasma FSH levels were observed. In a second set of experiments, the effect of DPA pretreatment (400 mg, orally) on gonadotropin release stimulated by a pulse of exogenous GnRH (10 μg, iv bolus) was studied in 11 subjects. During both follicular (n = 4) and luteal phase (n = 7), DPA did not modify gonadotropin response to GnRH injected 1h after pretreatment. Finally, 8 subjects were submitted to iv injection with 10 μg GnRH 2h after pretreatment with DPA (400 mg, orally) or placebo. During both follicular (n = 4) and luteal phase (n =4), no statistical differences in gonadotropin response to GnRH were found between DPA and placebo pretreatment. These findings demonstrated that during the estrogen-progesterone (midluteal) phase of menstrual cycle, endogenous GABA is involved in the inhibitory regulation of LH secretion at a central level.

Original languageEnglish
Pages (from-to)71-76
Number of pages6
JournalJournal of Endocrinological Investigation
Volume9
Issue number1
DOIs
Publication statusPublished - 1986

Fingerprint

Gonadotropins
Gonadotropin-Releasing Hormone
gamma-Aminobutyric Acid
Placebos
Follicular Phase
Luteal Phase
Menstrual Cycle
Valproic Acid
Anticonvulsants
Progesterone
Estrogens
Injections

Keywords

  • GABAergic system
  • gonadotropin
  • gonadotropin-releasing hormone
  • menstrual cycle
  • Sodium valproate

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Involvement of endogenous gabaergic system in the modulation of gonadotropin secretion in normal cycling women. / Melis, Gian Benedetto; Mais, V.; Paoletti, A. M.; Beneventi, F.; Petacchi, F. D.; Fioretti, P.

In: Journal of Endocrinological Investigation, Vol. 9, No. 1, 1986, p. 71-76.

Research output: Contribution to journalArticle

Melis, Gian Benedetto ; Mais, V. ; Paoletti, A. M. ; Beneventi, F. ; Petacchi, F. D. ; Fioretti, P. / Involvement of endogenous gabaergic system in the modulation of gonadotropin secretion in normal cycling women. In: Journal of Endocrinological Investigation. 1986 ; Vol. 9, No. 1. pp. 71-76.
@article{f67e72fbd3264a5ba57fde46a9f1e52f,
title = "Involvement of endogenous gabaergic system in the modulation of gonadotropin secretion in normal cycling women",
abstract = "To investigate whether endogenous GABA participates in the control of gonadotropin secretion during the menstrual cycle, placebo or sodium valproate (DPA), an anticonvulsant drug which enhances endogenous GABA content by blocking GABA degradation, were administered to regularly cycling women both during early follicular and midluteal phase. In a first set of experiments, the effect of DPA administration (400 mg, orally) on basal gonadotropin secretion was evaluated in 13 subjects. During early follicular phase (n = 6), no significant changes In plasma gonadotropin levels were observed after DPA or placebo administration. Conversely, during midluteal phase (n = 7), DPA administration resulted in a significant fall (p <0.01) in plasma LH concentrations, with a maximal percent decrease of 41.8 ± 6.7{\%} after 120 min. No changes in plasma FSH levels were observed. In a second set of experiments, the effect of DPA pretreatment (400 mg, orally) on gonadotropin release stimulated by a pulse of exogenous GnRH (10 μg, iv bolus) was studied in 11 subjects. During both follicular (n = 4) and luteal phase (n = 7), DPA did not modify gonadotropin response to GnRH injected 1h after pretreatment. Finally, 8 subjects were submitted to iv injection with 10 μg GnRH 2h after pretreatment with DPA (400 mg, orally) or placebo. During both follicular (n = 4) and luteal phase (n =4), no statistical differences in gonadotropin response to GnRH were found between DPA and placebo pretreatment. These findings demonstrated that during the estrogen-progesterone (midluteal) phase of menstrual cycle, endogenous GABA is involved in the inhibitory regulation of LH secretion at a central level.",
keywords = "GABAergic system, gonadotropin, gonadotropin-releasing hormone, menstrual cycle, Sodium valproate",
author = "Melis, {Gian Benedetto} and V. Mais and Paoletti, {A. M.} and F. Beneventi and Petacchi, {F. D.} and P. Fioretti",
year = "1986",
doi = "10.1007/BF03348068",
language = "English",
volume = "9",
pages = "71--76",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "1",

}

TY - JOUR

T1 - Involvement of endogenous gabaergic system in the modulation of gonadotropin secretion in normal cycling women

AU - Melis, Gian Benedetto

AU - Mais, V.

AU - Paoletti, A. M.

AU - Beneventi, F.

AU - Petacchi, F. D.

AU - Fioretti, P.

PY - 1986

Y1 - 1986

N2 - To investigate whether endogenous GABA participates in the control of gonadotropin secretion during the menstrual cycle, placebo or sodium valproate (DPA), an anticonvulsant drug which enhances endogenous GABA content by blocking GABA degradation, were administered to regularly cycling women both during early follicular and midluteal phase. In a first set of experiments, the effect of DPA administration (400 mg, orally) on basal gonadotropin secretion was evaluated in 13 subjects. During early follicular phase (n = 6), no significant changes In plasma gonadotropin levels were observed after DPA or placebo administration. Conversely, during midluteal phase (n = 7), DPA administration resulted in a significant fall (p <0.01) in plasma LH concentrations, with a maximal percent decrease of 41.8 ± 6.7% after 120 min. No changes in plasma FSH levels were observed. In a second set of experiments, the effect of DPA pretreatment (400 mg, orally) on gonadotropin release stimulated by a pulse of exogenous GnRH (10 μg, iv bolus) was studied in 11 subjects. During both follicular (n = 4) and luteal phase (n = 7), DPA did not modify gonadotropin response to GnRH injected 1h after pretreatment. Finally, 8 subjects were submitted to iv injection with 10 μg GnRH 2h after pretreatment with DPA (400 mg, orally) or placebo. During both follicular (n = 4) and luteal phase (n =4), no statistical differences in gonadotropin response to GnRH were found between DPA and placebo pretreatment. These findings demonstrated that during the estrogen-progesterone (midluteal) phase of menstrual cycle, endogenous GABA is involved in the inhibitory regulation of LH secretion at a central level.

AB - To investigate whether endogenous GABA participates in the control of gonadotropin secretion during the menstrual cycle, placebo or sodium valproate (DPA), an anticonvulsant drug which enhances endogenous GABA content by blocking GABA degradation, were administered to regularly cycling women both during early follicular and midluteal phase. In a first set of experiments, the effect of DPA administration (400 mg, orally) on basal gonadotropin secretion was evaluated in 13 subjects. During early follicular phase (n = 6), no significant changes In plasma gonadotropin levels were observed after DPA or placebo administration. Conversely, during midluteal phase (n = 7), DPA administration resulted in a significant fall (p <0.01) in plasma LH concentrations, with a maximal percent decrease of 41.8 ± 6.7% after 120 min. No changes in plasma FSH levels were observed. In a second set of experiments, the effect of DPA pretreatment (400 mg, orally) on gonadotropin release stimulated by a pulse of exogenous GnRH (10 μg, iv bolus) was studied in 11 subjects. During both follicular (n = 4) and luteal phase (n = 7), DPA did not modify gonadotropin response to GnRH injected 1h after pretreatment. Finally, 8 subjects were submitted to iv injection with 10 μg GnRH 2h after pretreatment with DPA (400 mg, orally) or placebo. During both follicular (n = 4) and luteal phase (n =4), no statistical differences in gonadotropin response to GnRH were found between DPA and placebo pretreatment. These findings demonstrated that during the estrogen-progesterone (midluteal) phase of menstrual cycle, endogenous GABA is involved in the inhibitory regulation of LH secretion at a central level.

KW - GABAergic system

KW - gonadotropin

KW - gonadotropin-releasing hormone

KW - menstrual cycle

KW - Sodium valproate

UR - http://www.scopus.com/inward/record.url?scp=0022504105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022504105&partnerID=8YFLogxK

U2 - 10.1007/BF03348068

DO - 10.1007/BF03348068

M3 - Article

C2 - 3084617

AN - SCOPUS:0022504105

VL - 9

SP - 71

EP - 76

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 1

ER -